Ind-Swift Limited, a pharmaceutical company, manufactures and sells finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It has a portfolio of approximately 750 products with presence in therapeutic segments of cardiology, diabetology, anti-depressant, anti-allergic, anti-infective, neurology, and oncology. The company offers medicines for the respiratory, including ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies; a range of medicines for gynecology, pediatrics, dermatology, and GP; and antibiotics, anti-infectives, anti-cold, nutraceuticals, anti-convulsants, analgesics, anti-diarrheal, anti-allergics, anti-inflammatory and anti-ulcer drugs, hypolipidaemic drugs, anti-malarial, enzymes, expectorants, antipsychotics, and anti-depressants for treating common ailments, such as fever, cough, cold, diarrhoea, body ache, and infections. It also provides medicines to government dispensaries, hospitals, and remote and rural areas; and Ayurveda products. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India. The ISIN of this stock is INE788B01028.